Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also known as BAX 930/SHP655) in the prophylactic and on-demand treatment of subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP; Upshaw Schulman Syndrome, or hereditary thrombotic thrombocytopenic purpura)

Next Previous
Trial Profile

A Phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also known as BAX 930/SHP655) in the prophylactic and on-demand treatment of subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP; Upshaw Schulman Syndrome, or hereditary thrombotic thrombocytopenic purpura)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apadamtase alfa (Primary) ; Apadamtase alfa (Primary)
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Adverse reactions; Registrational
  • Sponsors Baxalta Innovations GmbH; Takeda

Most Recent Events

  • 02 Apr 2026 Status changed from recruiting to active, no longer recruiting.
  • 10 Dec 2024 Results (n=6) presented at the 66th American Society of Hematology Annual Meeting and Exposition.
  • 25 Nov 2024 According to a Takeda media release, data from this study will be presented at at the 66th American Society of Hematology (ASH) Annual Meeting being held December 7-10, 2024, in San Diego, California.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top